Navigation Links
New Drug Shows Promise Against Huntington's Disease
Date:11/7/2011

MONDAY, Nov. 7 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.

Huntington's patients have an imbalance in the signaling chemical dopamine. The new drug stabilizes dopamine signaling in areas of the brain that control movement and coordination.

According to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily. The only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.

The results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.

The study included 437 Huntington's disease patients from eight European countries. The participants took either pridopidine (45 milligrams once daily or 45 mg twice daily) or a placebo for 26 weeks.

After six months of treatment, patients taking the higher dose of pridopidine showed improvements in motor function -- specifically in eye and hand movements, involuntary muscle contractions (dystonia), and gait and balance -- compared with patients taking the placebo.

More than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers. Side effects among patients taking the drug were similar to the placebo group.

"Pridopidine has the potential to complement available treatments by improving a different range of motor deficits. Its lack of severe side-effects . . . suggests that pridopidine might be useful even for those patients who are treated at sites that are not centers of excellence for Huntington's disease," the researchers concluded.

One U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.

"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease," said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.

"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease. And, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last," he added.

Still, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.

"Unfortunately, Huntington's is a progressive disease and this drug is not a treatment of the disease itself but only improves some of its symptoms," he explained. "Nevertheless, it is a welcome addition because there is very little else yet available to treat the symptoms. The challenge for scientists and clinicians is to discover therapies that actually slows or halts the progression of the disease."

Another expert agreed that new treatment options for patients are sorely needed.

"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder," Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.

The study was funded by European pharmaceuticals company NeuroSearch A/S.

More information

We Move has more about Huntington's disease.

-- Robert Preidt

SOURCES: Alessandro Di Rocco, M.D., professor, department of neurology and chief, division of movement disorders, NYU Langone Medical Center, New York City; The Lancet Neurology, news release, Nov. 7, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene therapy shows promise as hemophilia treatment in animal studies
2. Exenatide (Byetta) has rapid, powerful anti-inflammatory effect, UB study shows
3. New drug shows promise against multiple sclerosis
4. Preterm birth rate shows three year improvement in most states
5. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
6. Novel approach to treat proliferative vitreoretinopathy shows promise
7. New therapy shows promise for treating cardiovascular disease
8. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
9. New oncolytic virus shows improved effectiveness in preclinical testing
10. Clinical trial shows first evidence that anal cancer is preventable
11. Through-the-nipple breast cancer therapy shows promise in early tests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Shows Promise Against Huntington's Disease
(Date:10/13/2017)... Fort Worth, TX (PRWEB) , ... October 13, ... ... and financial planning agency serving communities in the greater Dallas, Miami, and Raleigh ... a young boy fighting to overcome a rare and deadly chromosome abnormality. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology: